Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutations

Limb-girdle muscular dystrophy recessive 1 (LGMDR1), previously known as LGMD2A, is a rare disease caused by mutations in the CAPN3 gene. It is characterized by progressive weakness of shoulder, pelvic, and proximal limb muscles that usually appears in children and young adults and results in loss o...

Descripción completa

Detalles Bibliográficos
Autores: Lasa Elgarresta, Jaione, Mosqueira Martín, Laura, Naldaiz Gastesi, Neia, Sáenz Peña, Amets, López de Munain Arregui, Adolfo José, Vallejo Illaramendi, Ainara
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/37572
Acceso en línea:http://hdl.handle.net/10810/37572
Access Level:acceso abierto
Palabra clave:calpain 3
calcium
LGMD2A
LGMDR1
muscular dystrophies
calpainopathy
NF-kappa B
permeability transition pore
muscle-specific calpain
skeletal-muscle
oxidative stress
in-vivo
sarcoplasmic-reticulum
mitochondrial activity
proteolytic activity
genetic isolate
Descripción
Sumario:Limb-girdle muscular dystrophy recessive 1 (LGMDR1), previously known as LGMD2A, is a rare disease caused by mutations in the CAPN3 gene. It is characterized by progressive weakness of shoulder, pelvic, and proximal limb muscles that usually appears in children and young adults and results in loss of ambulation within 20 years after disease onset in most patients. The pathophysiological mechanisms involved in LGMDR1 remain mostly unknown, and to date, there is no effective treatment for this disease. Here, we review clinical and experimental evidence suggesting that dysregulation of Ca2+ homeostasis in the skeletal muscle is a significant underlying event in this muscular dystrophy. We also review and discuss specific clinical features of LGMDR1, CAPN3 functions, novel putative targets for therapeutic strategies, and current approaches aiming to treat LGMDR1. These novel approaches may be clinically relevant not only for LGMDR1 but also for other muscular dystrophies with secondary calpainopathy or with abnormal Ca2+ homeostasis, such as LGMD2B/LGMDR2 or sporadic inclusion body myositis.